https://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trialhttps://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trial#u46940Sun, 23 Aug 2026 13:46:30 +0000A personalized mRNA vaccine developed by Moderna and Merck has shown promising results in preventing skin cancer from recurring in patients. The vaccine, which is tailored to individual tumors, successfully completed phase 3 clinical trials for treating melanoma. This milestone is the final step required before the drugmakers can seek approval from the FDA.Why it mattersThe treatment aims to stop skin cancer from returning or spreading. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma. The vaccine's success in clinical tri https://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trialhttps://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trial#u45974Fri, 21 Aug 2026 20:35:55 +0000A personalized mRNA vaccine developed by Moderna and Merck successfully completed phase 3 clinical trials for treating melanoma. The treatment aims to stop skin cancer from returning or spreading by tailoring the vaccine to individual tumors. This milestone is the final step required before the drugmakers can seek approval from the FDA. Researchers believe this personalized approach could eventually be applied to other types of cancer beyond melanoma.Why it mattersThe vaccine adapts mRNA technology previously used in Covid-19 vaccines for oncology. Moderna and Merck shares hit 52-week highs fo https://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trialhttps://www.live-feeds.com/feed/vaccine-breakthrough-stops-cancer-returning-in-trial#u45740Fri, 21 Aug 2026 04:15:59 +0000A late-stage trial of an mRNA vaccine developed by Moderna and Merck shows promise in stopping cancer from returning. The treatment specifically targets the recurrence and spread of skin cancer. Following the announcement, Moderna and Merck shares reached 52-week highs, with Moderna stock seeing significant gains. This development marks a shift for Moderna as it applies its mRNA technology from Covid-19 vaccines to oncology.Why it mattersmRNA technology allows for the creation of vaccines tailored to specific proteins. Reducing cancer recurrence is a critical goal in oncology to prevent late-s